Innovaderm’s Prominent Role in Advancing Dermatology Research at Highlighted During Another LEO Pharma’s Late-Breaking Session at EADV Congress in Amsterdam, The Netherlands

Innovaderm’s prominent role in advancing dermatology research was highlighted once more during a late-breaking session at the European Academy of Dermatology and Venereology (EADV) on September 27th in Amsterdam.

The abstract “Randomized vehicle-controlled clinical trial with the topical JAK inhibitor delgocitinib in patients with frontal fibrosing alopecia demonstrates biomarker and clinical efficacy” was authored by our founder and CEO, Dr. Robert Bissonnette, alongside Maryanne Makredes Senna, Ole Erik Soerensen, Anders Bacher Nielsen, and Emma Guttman.

The primary outcome of this LEO Pharma-sponsored phase II trial measured the change in expression of CXCL9, CXCL10 and IFN-γ proteins from baseline to Week 12 in adults with frontal fibrosing alopecia.

Innovaderm is proud to be a key player in dermatology clinical initiatives, making a significant impact on the lives of patients suffering from skin diseases.

___

Le rôle important d’Innovaderm dans l’avancement de la recherche en dermatologie a été souligné une fois de plus lors d’une séance de dernière minute à l’Académie européenne de dermatologie et de vénéréologie (EADV) le 27 septembre à Amsterdam.

La session « Randomized vehicle-controlled clinical trial with the topical JAK inhibitor delgocitinib in patients with frontal fibrosing alopecia demonstrates biomarker and clinical efficacy » a été présentée par notre fondateur et PDG, Dr Robert Bissonnette, aux côtés de Maryanne Makredes Senna, Ole Erik Soerensen, Anders Bacher Nielsen, et Emma Guttman.

Innovaderm est fière de jouer un rôle clé dans des initiatives cliniques en dermatologie, ayant un impact significatif sur la vie des patients souffrant de maladies de la peau.

Newsletter